Last update: Dec. 4, 2020

Zanamivir

Very Low Risk for breastfeeding


Safe. Compatible.
Minimal risk for breastfeeding and infant.

Used in the treatment and prophylaxis of influenza A and B.
Administered via inhalation or intravenously in two daily doses.

The low plasma concentrations reached make it unlikely that significant amounts will transfer into breastmilk (Tanaka 2009).

Its very low oral absorption, 2% (Cass 1999), prevents transfer into infant plasma from breastmilk (Skalli 2010, Tanaka 2009).

Its use is authorized in infants from 6 months of age.

Various medical associations and expert consensus consider its use to be safe during breastfeeding (Skalli 2010, Chen 2010, Tanaka 2009, ABM 2009, AEM 2009).


See below the information of this related product:

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Zanamivir in other languages or writings:

Group

Zanamivir belongs to this group or family:

Tradenames

Main tradenames from several countries containing Zanamivir in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. oral: 2 ; inhal: 17 %
Molecular weight 332 daltons
Protein Binding < 10 %
pKa 3,25 -
Tmax 1 - 2 hours
T1/2 2,5 - 5,1 hours
Theoretical Dose < 0,015 (probable) mg/Kg/d
Relative Dose < 4,5 (probable) %
Ped.Relat.Dose < 0,8 (probable) %

References

  1. Skalli S, Ferreira E, Bussières JF, Allenet B. Grippe A/H1N1v 2009, grossesse et allaitement: quel antiviral choisir? [Influenza A/H1N1v 2009 during pregnancy and breastfeeding: which antiviral to choose?]. Ann Pharm Fr. 2010 Abstract
  2. Chen LH, Zeind C, Mackell S, LaPointe T, Mutsch M, Wilson ME. Breastfeeding travelers: precautions and recommendations. J Travel Med. 2010 Jan-Feb;17(1):32-47. Abstract Full text (link to original source) Full text (in our servers)
  3. Tanaka T, Nakajima K, Murashima A, Garcia-Bournissen F, Koren G, Ito S. Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women. CMAJ. 2009 Abstract Full text (link to original source) Full text (in our servers)
  4. Academy of Breastfeeding Medicine. Breastfeeding / Swine Flu Recommendations for Physicians from the Academy of Breastfeeding Medicine For immediate release (ABM) 2009 Full text (in our servers)
  5. PDR Zanamivir Drug Summary 2009 Full text (in our servers)
  6. Agencia Española del Medicamento Uso de Oseltamivir y Zanamivir en niños de cualquier edad, en mujeres gestantes y mujeres en periodo de lactancia y en personas con problemas de deglución. \ Nota Informativa 2009 Full text (in our servers)
  7. Cass LM, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet. 1999 Abstract

Total visits

8,367

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2021 from United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM